Coloplast As Sp/Adr (CLPBY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Coloplast financial statement for the full year 2024-2025 and annual report 2024-2025 conference call. I am Sandra, the course call operator. I would like to remind you that all participants have been disanonymized and the conference has been recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Lars Rasmussen, Interim CEO. Please go ahead. Thank you and good morning and welcome to our full year 24-25 conference call. I'm Lars Rasmussen, interim CEO of Coloplast and I'm joined by Anders Lonning-Skovgaard, our CFO and by our investor relations team. We will start with a short presentation by Anders and myself and then open up for questions. Please turn to slide number three. We delivered 7% organic growth and a reported EBIT margin before special items of 28% for this financial year. That is in line with our revised guidance, but below the 8-9% organic growth expectations that we set forth at the beginning of the year. The adjusted return on invested capital after tax and before special items was 15% on power last year. Chronic care, including voice and respiratory care and excluding China, delivered a solid year while we faced performance challenges in interventional neurology and advanced wound dressings. Both businesses were impacted by product recalls with significant negative impact on performance. We also saw increased volatility in the biologics markets, driven by the postponement of the final LCD policy, which led to a slowdown in the momentum for keresis in the secon...